Starting next month, hospices will have to report to Medicare all nursing, hospice aide, and social worker visits made for patients. Then a few months later, the new conditions of participation (COPs) will be finalized, which will require greater attention to documentation of services and quality.
Whether it's new onset or established disease, the PCP has an arsenal of diagnostic tests available. The array of tests, however, can be quite daunting in identifying the right test to order, especially in light of sensitivity and specificity, not to mention cost. This issue provides the PCP with a comprehensive survey of the diagnostic tests available, a guide to selection, an estimate of cost, and limitations of each test.
FDA warnings for existing drugs dominate pharmaceutical news this month. These warnings represent a new push by the FDA to regulate existing drugs for safety after they have been approved for marketing. It also comes at a time when the FDA is cleaning up its advisory committee processes, especially with regard to limiting potential conflict of interest by advisory committee members.
A calcium score < 100 eliminates the need for MPS, but patients with a negative MPS often have coronary calcium. These findings imply a potential role for applying CAC screening after MPS among patients manifesting normal MPS.